Prominent Players - Human Platelet Lysate Industry

Over the course of the projection period, top businesses and governments are anticipated to increase their stem cell therapy research and development (R&D) efforts. Over the course of the projection period, leading players are anticipated to increase their use of inorganic growth tactics, such as partnerships. For instance, on March 11, 2022, the multinational information technology giant Wipro announced a partnership with the biotechnology firm Pandorum Technologies to develop regenerative medicine.

The market for Human Platelet Lysate is anticipated to reach a value of US$ 53.0 million in 2023 and grow at a CAGR of 4.54% from 2023 to 2030.

Key Competitors in the Human Platelet Lysate Industry:

STEMCELL Technologies Inc.:

1. Established in 1993. Headquarters in Canada. Producer of tools for life science research. Cell culture medium and supplements, cell separation products, primary and cultured cells, cytokines, matrices, and substrates are among the company's goods that enable researchers throughout the world to conduct studies on stem cells, immunology, cancer, regenerative medicine, and cellular therapy. Animal health industry leader Boehringer Ingelheim has purchased Belgian veterinary biotech firm Global Stem Cell Technology (GST).

Merck KGaA:

2. Founded in 1891. German headquarters are in Darmstadt. The three primary business sectors of Merck KGaA are life sciences, performance materials, and healthcare. Researchers in academia and applied disciplines, such as the biopharmaceutical industry, are principally served by the life sciences segment (47% of 2022 sales), which also offers laboratory supplies and services. Merck discovers, produces, and distributes branded drugs with major therapeutic concentrations in oncology, multiple sclerosis, and fertility in the healthcare industry (35%). The business provides speciality materials to make a range of goods, including semiconductors, flat-screen televisions, cars, and cosmetics, under its electronics section (18%). The E. Merck KG family publicly sold a portion of the business in 1995, which led to the current 30% public ownership of the business.

Mill Creek Life Sciences:

3. Founded in 2010. Headquarters in the United States. Creator of a human platelet lysate intended to quicken treatments for regenerative medicine. The company's product is made from human platelets and delivers unmatched stem cell proliferation at a low cost, allowing researchers to augment the primary cells and stem cell cultures utilised in clinical and research applications.  Alister Nanuet has been acquired by Mill Creek Residential, a prominent multifamily investor, developer, and operator with a focus on luxury apartment communities in the U.S. This is the company's eighth acquisition in the last 12 months.

AventaCell BioMedical:

4. Founded in 2015. Headquarters in Taiwan's Taipei. biochemicals for tissue engineering and cell culture. The business produces specialised cell culture supplements under the names UltraGRO for commercial and medical uses and BSSub-XF for research uses.

Macopharma SA:

5. The French Company Macopharma, which was established in 1977, is a significant player in the blood sector. Its growth has always been fueled by significant breakthroughs produced by sizable investments in R&D and partnerships formed with clients and business partners. In order to assist healthcare professionals in providing donors and patients with safer and higher-quality blood components, Macopharma will offer a variety of blood processing solutions in 2023. These solutions combine knowledge in disposables, equipment, software, and processing standards.

PL BioScience GmbH:

6. Founded in 2015. German headquarters are in Aachen. Creator of services for animal-free cell culture aimed at bridging the gap between academic and commercial uses. Through the company's services, biotech companies and life sciences organisations can meet the rising demand for cell culture media for all stages of stem cell research and development. These supplements are made from old human platelets that have undergone a freeze-thaw process to induce the release of growth factors. In order to deliver its selection of human platelet lysate to markets across North America, Captivate Bio, a provider of scientific cell culture products, today announced it had inked an exclusive distribution deal with PL BioScience GmbH, a biotech firm based in Aachen, Germany.

BBI Solutions:

7. Built in 1986. Welsh headquarters in the United Kingdom.For the food, healthcare, research, defence, and diagnostic industries, immunoassay and diagnostic product developers and manufacturers. With a portfolio of goods and services that includes gold reagents, antibodies, antigens, enzymes, serum, and plasma, cell culture reagents, as well as antibody development services, mobile diagnostic solutions, and lateral flow assay development, the company provides technologies for rapid sampling and identification of biothreats and explosives, women's health, energy, and digestive products. Today, "Biotez" was acquired by BBI Solutions, the top independent global supplier of immuno-diagnostic reagents and contract services.

*Definition: 

Human platelet lysate is a growth factor-rich cell culture supplement derived from healthy donor human platelets. Fetal bovine serum (FBS) can be substituted with human platelet lysate (HPL) in both experimental and clinical cell culture.